Henry Schein, Inc. (HSIC)

Henry Schein's stock has been influenced by several key events in the past six months. The company reported strong third-quarter 2025 financial results with accelerating sales growth across all segments and solid market share gains, raising its 2025 guidance for non-GAAP diluted EPS and total sales growth. Henry Schein reported its highest sales growth in 15 quarters for Q4 2025 and introduced 2026 financial guidance, expecting non-GAAP diluted EPS in the range of $5.23 to $5.37 and total sales growth of approximately 3% to 5% over 2025. Henry Schein announced plans to reduce its board from 15 to 10 directors following the May 21 annual meeting, with Frederick Lowery taking over as CEO as of March 2026. Investor attention has been focused on KKR's strategic stake, with an agreement reached in Q3 2025 to provide KKR the right to increase its HSIC stock ownership up to 19.9%. Following strong Q4 earnings and constructive analyst sentiment, some firms raised price targets, with the analyst consensus average target sitting near $90. As of April 10, 2026, Henry Schein's stock was up 14.3% over the past year.

Henry Schein experiences some demand seasonality in its various business segments. Flu vaccine sales in the medical business can impact gross margins, leading to sequential declines in certain quarters, such as Q3 2025. Weather-related events can cause a slow start to sales in certain months, as seen with U.S. dental merchandise sales in January 2025. The company has reported strong sales momentum in its global equipment, specialty products, and technology businesses, particularly in the second half of 2025.

Henry Schein, Inc. is a global provider of healthcare products and services, primarily serving office-based dental, medical, and animal health practitioners. The company operates within the Health Care Equipment & Services sector. Its business is segmented into Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. The Global Distribution and Value-Added Services segment offers consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, vitamins, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, high-tech and digital restoration equipment, financial services, continuing education, and consulting, and markets its own corporate brand merchandise. The Global Specialty Products segment manufactures, markets, and sells dental implant and biomaterial products, as well as endodontic, orthodontic, and orthopedic products and other healthcare-related products and services. The Global Technology segment develops and distributes practice management software, e-services, and other technology products for healthcare providers.

Henry Schein, Inc. has a significant global presence, with operations or affiliates in 34 countries and territories, serving over 1 million customers worldwide. Its distribution network includes 9 core North American distribution centers serving dental and medical, 8 in Europe for dental and medical, 4 in Australia/New Zealand for dental, and 7 in Asia/Rest of World for dental. Overall, Henry Schein has 28 warehouses globally, encompassing over 3.5 million square feet for storage and processing.

Henry Schein, Inc. has maintained a positive brand reputation, evidenced by its recognition as one of the 2026 World's Most Ethical Companies® by Ethisphere for the 15th consecutive year, highlighting the company's commitment to business integrity through robust ethics, compliance, and governance programs.

Henry Schein's ownership is characterized by a significant presence of institutional investors, holding 87.2% of the company's shares as of March 31, 2025. Individual insiders account for approximately 1.2%, while private companies hold around 11.5%. Key institutional holders include Kohlberg Kravis Roberts & Co. L.P., Vanguard Group Inc., BlackRock, Inc., Artisan Partners Limited Partnership, JPMorgan Chase & Co., Invesco Ltd., and State Street Corp.